exciting agents and treatment approaches emerging in the field of myelofibrosis
Published 2 months ago • 190 plays • Length 2:13Download video MP4
Download video MP3
Similar videos
-
1:04
exciting updates in mf: novel targets and agents
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
4:48
an insight into the management of cytopenias in mf
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
2:21
targeted therapy for mds
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
6:24
indiko biochemistry analyzer demonstration
-
2:07
"giải thích case bệnh: tác dụng của adrenaline khi tiêm vào nội khí quản " | eduvet
-
9:29
mds/aml overlap and novel therapies with dr. naval daver
-
1:14
promising novel agents in aml: menin inhibitors
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
8:31
targeting bcl-2 in mds
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
3:35
the potential of mrd as a surrogate marker in randomized trials to accelerate drug approvals
-
2:41
an overview of the latest advances in hematology
-
0:45
difference between quality of life & patient-reported outcomes
-
1:05
the importance of using mrd to guide treatment decisions in all
-
1:02
role of hypomethylating agents in the novel agent era
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis